Is 7-OH an opioid?

At a glance: is 7-OH an opioid?

Key Takeaways

• 7-OH is an opioid. Plant origin does not change pharmacological classification. 7-OH activates mu-opioid receptors, which defines it as an opioid regardless of where it comes from.
• "Opioid" is not the same as "opiate." Opiate is a narrower term meaning derived from the opium poppy. Opioid covers any substance that acts on opioid receptors, including synthetic and plant-derived compounds not from the poppy. 7-OH is an opioid but not an opiate.
• 7-OH is potent. The FDA's 2025 scientific assessment documented respiratory depression from 7-OH at more than three times morphine's potency. Commercial extract products deliver it at concentrations far above what the kratom leaf naturally contains.
• Because 7-OH is an opioid, opioid treatment works for dependence on it. Buprenorphine (Suboxone), the evidence-based medication for opioid use disorder, stabilizes the same receptors 7-OH activates. Many people who developed 7-OH dependence did not know it was an opioid until they tried to stop.

Why 7-OH is an opioid: the mechanism

The defining feature of an opioid is not its origin — it is what it does at opioid receptors. The body has a system of opioid receptors (mu, delta, and kappa) that are activated by endogenous compounds like endorphins and by exogenous opioids from external sources.

7-Hydroxymitragynine binds and activates the mu-opioid receptor — the receptor that is also activated by morphine, oxycodone, heroin, fentanyl, and buprenorphine. When 7-OH activates this receptor, it produces the same downstream effects those compounds produce: analgesia, euphoria, sedation, slowed breathing, and the neuroadaptation that underlies physical dependence.

The pharmacological literature (Obeng et al., Journal of Pharmacology and Experimental Therapeutics, 2021) confirmed that 7-OH has both high binding affinity and meaningful intrinsic efficacy at the mu-opioid receptor. The FDA's 2025 scientific assessment described 7-OH as a "novel potent opioid" and treated it as such in its regulatory analysis. The DEA's July 2026 scheduling notices explicitly categorized it as an opioid substance for regulatory purposes.

Plain-language summary: Yes, 7-OH is an opioid. Although it comes from the kratom plant rather than the opium poppy, 7-hydroxymitragynine activates the body's mu-opioid receptors the same way morphine does.

Opioid vs. opiate: why the wording matters

The distinction between these two terms is more than semantic. Vendors and marketers of kratom and 7-OH products frequently use the botanical origin of the product to imply it is not a "real drug" or does not carry opioid risks. Understanding the terminology makes that argument transparent.

Opiate is the older and narrower term, referring specifically to compounds derived from the opium poppy (Papaver somniferum): morphine, codeine, and thebaine are opiates. Heroin, oxycodone, and hydrocodone are semi-synthetic opiates, derived from opium poppy alkaloids through chemical modification.

Opioid is the broader pharmacological term, covering any substance — natural, semi-synthetic, or synthetic — that acts on opioid receptors. This includes opiates but also fully synthetic compounds (fentanyl, methadone) and plant-derived compounds from non-poppy sources (kratom alkaloids).

7-OH is an opioid but not an opiate. It comes from the kratom plant (Mitragyna speciosa), not the opium poppy. Its pharmacological activity — mu-opioid receptor binding and activation — is what makes it an opioid.

7-OH is an opioid but not an opiate — it acts like poppy-derived opioids without coming from the poppy.

How potent is 7-OH?

Is 7-OH stronger than morphine?

In laboratory receptor studies, 7-OH demonstrates higher binding affinity and greater potency than morphine at the mu-opioid receptor. The FDA's 2025 scientific assessment documented that 7-OH produces respiratory depression at more than three times the potency of morphine in preclinical research — a figure based on the clinical outcome most relevant to overdose risk.

Some receptor binding studies show even larger potency ratios (sometimes cited as 13 to 30 times morphine), but these figures come from in vitro binding assays, which measure affinity rather than clinical effect. The FDA's respiratory depression figure is the measure most directly relevant to patient safety and is the figure the agency itself used in its regulatory assessment.

7-OH vs. mitragynine: the potency gap in kratom

Mitragynine is the primary alkaloid in kratom leaf, making up 60 to 70% of leaf alkaloid content. It is also a mu-opioid receptor agonist, but substantially weaker than 7-OH at that receptor. Research has documented that 7-OH is significantly more potent than mitragynine per molecule.

Traditional kratom leaf contains 7-OH at trace concentrations of 0.003% to 0.04% by dry weight. Most of the 7-OH effect from leaf use actually comes from the body metabolizing some mitragynine into 7-OH in the liver — a controlled, limited conversion. Commercial concentrated 7-OH products deliver 7-OH directly at 22 to 75 milligrams per gram (documented in peer-reviewed analysis), concentrations achievable only through chemical synthesis.

This potency gap is the regulatory rationale behind the DEA's July 2026 decision to target concentrated 7-OH while explicitly leaving natural kratom leaf below the threshold alone.

What it means that 7-OH is an opioid

Dependence and withdrawal

Because 7-OH activates mu-opioid receptors, regular use produces the same neuroadaptation as any other opioid. The brain responds to sustained receptor activation by reducing receptor sensitivity and adjusting neurotransmitter systems. When 7-OH is stopped, the adapted system goes into deficit — producing opioid withdrawal symptoms: muscle aches, sweating, anxiety, insomnia, nausea, diarrhea, and strong cravings.

7-OH withdrawal follows the standard opioid withdrawal timeline and symptom profile, though concentrated product users often experience a faster onset (6 to 12 hours after the last dose) and more intense peak than traditional kratom leaf users. For the full withdrawal picture, see 7-OH Withdrawal Symptoms.

Overdose risk

Like other opioids, 7-OH at high doses suppresses breathing. The FDA's 2025 assessment documented dose-dependent respiratory depression reversible with naloxone, consistent with classical opioid toxicology. Concentrated 7-OH products deliver 7-OH at potencies that carry meaningful overdose risk, particularly when combined with other central nervous system depressants like alcohol, benzodiazepines, or other opioids. Naloxone (Narcan) can reverse the opioid component of a 7-OH overdose; always call 911 in any suspected overdose situation.

Regulatory status

7-OH is not FDA-approved for any medical use. In July 2026, the DEA filed notices of intent to temporarily place concentrated 7-OH (above 0.05% by dry weight, or more than 1 mg per article in synthetic products) in Schedule I. Once the temporary order takes effect — not before August 5, 2026 — manufacturing, distribution, sale, and possession of covered products become subject to federal controlled substance penalties.

Someone using commercial 7-OH products is using an unregulated opioid outside any medical framework, with no standardized dosing, no contamination testing, and no clinical oversight.

If you developed 7-OH dependence not knowing it was an opioid

Many people started using 7-OH products because they were sold at gas stations and supplement stores as a natural product. The supplement framing — combined with the legal status at the time and the absence of standard drug test detection — made the opioid nature of the product invisible. People who tried to stop and found it unexpectedly difficult learned through withdrawal what the product actually was.

This is a pharmacologically predictable outcome of an opioid. It is not a character failure, and the dependence that developed is treatable through the same pathway used for opioid use disorder from any source.

Because 7-OH is an opioid, buprenorphine (Suboxone) — the standard evidence-based treatment for opioid use disorder — works directly for 7-OH dependence. It stabilizes the same mu-opioid receptors 7-OH was activating, preventing withdrawal and cravings, and blocking the reinforcing effect of any 7-OH used during treatment.

Treatment is available through telehealth in most states, often the same day. For how the mechanism works, see Does Suboxone Block 7-OH?

Frequently Asked Questions

Is 7-OH a narcotic?

In pharmacological terms, narcotic historically referred to opioids that produce sleep or stupor, and is now often used loosely to mean any opioid. In federal law, narcotics are defined as Schedule I and II controlled substances including opioids. Once the DEA's temporary scheduling order for concentrated 7-OH takes effect, it will meet the federal legal definition of a narcotic as a Schedule I controlled substance. Pharmacologically, it is an opioid.

Is kratom an opioid?

Kratom's primary alkaloid, mitragynine, is a partial agonist at mu-opioid receptors, which makes kratom pharmacologically opioid-acting. The classification is more nuanced than for 7-OH because mitragynine also acts at other receptor systems and its opioid potency is lower. The FDA describes kratom as having opioid properties. 7-OH, the concentrated alkaloid in extract products, is more definitively opioid in its receptor profile and clinical effects.

Is 7-OH addictive?

Yes. 7-OH produces physical dependence and, in many users, compulsive use patterns consistent with opioid use disorder — difficulty stopping, dose escalation, continued use despite harm. Published clinical guidance from Barrett et al. (AIM Clinical Cases, 2026) recommends treating 7-OH dependence as opioid use disorder. The DSM-5 criteria for substance use disorder apply to 7-OH dependence as they do to other opioids.

Is 7-OH safe because it comes from a plant?

No. Plant origin does not determine safety for opioid-acting compounds. Morphine and codeine are plant-derived opioids; that origin does not make them safe in uncontrolled use. For 7-OH specifically, commercial products are semi-synthetic (chemically manufactured from mitragynine), unregulated, inconsistently dosed, and documented to contain contaminants including heavy metals. The "natural supplement" framing is marketing, not pharmacology.